Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Bortezomib Refractory Multiple Myeloma”

167 trials

Showing 20 of 167 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04181827
What this trial is testing

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 419
Testing effectiveness (Phase 2)Study completedNCT01720875
What this trial is testing

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Who this might be right for
Multiple Myeloma
University of Leeds 16
Testing effectiveness (Phase 2)Looking for participantsNCT07227311
What this trial is testing

Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 200
Early research (Phase 1)Study completedNCT00664898
What this trial is testing

The Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03314181
What this trial is testing

Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 156
Large-scale testing (Phase 3)Active Not RecruitingNCT06956170
What this trial is testing

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 21
Large-scale testing (Phase 3)Study completedNCT01734928
What this trial is testing

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 559
Large-scale testing (Phase 3)Study completedNCT01311687
What this trial is testing

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Who this might be right for
Multiple Myeloma
Celgene 455
Early research (Phase 1)Ended earlyNCT01309412
What this trial is testing

CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 9
Early research (Phase 1)Study completedNCT01965353
What this trial is testing

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Dana-Farber Cancer Institute 21
Testing effectiveness (Phase 2)Ended earlyNCT00243035
What this trial is testing

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
National Cancer Institute (NCI) 64
Testing effectiveness (Phase 2)Study completedNCT00920855
What this trial is testing

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Cephalon 40
Early research (Phase 1)Study completedNCT00153933
What this trial is testing

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapsed Multiple MyelomaMultiple Myeloma
Dana-Farber Cancer Institute 58
Testing effectiveness (Phase 2)Study completedNCT03544281
What this trial is testing

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 153
Testing effectiveness (Phase 2)Ended earlyNCT00985907
What this trial is testing

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaPatient Participation
University of California, San Francisco 13
Testing effectiveness (Phase 2)Study completedNCT00315757
What this trial is testing

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Human Genome Sciences Inc. 105
Testing effectiveness (Phase 2)Study completedNCT01913730
What this trial is testing

Maintenance Therapy With Subcutaneous Bortezomib

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 63
Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Not applicableNo Longer AvailableNCT00063791
What this trial is testing

Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT00441168
What this trial is testing

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen-Cilag International NV 30
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation